Interleukins Patents (Class 435/69.52)
-
Publication number: 20120087900Abstract: The present invention is directed to adoptive immunotherapy using a lymphocyte in which an antigen-specific receptor and a bioactive material gene such as an IL-2 gene or a water-soluble TGF-beta receptor gene are transferred. The bioactive material is intensively secreted to, for example, a local site of a tumor, thereby reducing systemic side effects as much as possible, and the survival time of the lymphocyte is increased, thereby further improving the effect of the adoptive immunotherapy.Type: ApplicationFiled: April 1, 2011Publication date: April 12, 2012Applicant: CATHOLIC UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATIONInventor: Tai-Gyu KIM
-
Publication number: 20120082996Abstract: IL-21 variants nucleic acid sequences are provided that encode a peptide having deletions and zero to ten conservative amino acid substitutions in the region of amino acid residues 65-96 of SEQ ID. NO:2.Type: ApplicationFiled: September 19, 2011Publication date: April 5, 2012Inventors: Siv Annegrethe Hjorth, Kent Bondensgaard, Dennis Madsen
-
Publication number: 20120082644Abstract: The present invention provides methods of regulating an immunological disorder comprising administering to a subject an effective amount of (i) an autoimmune antigen in conjunction with (ii) an anti-inflammatory cytokine. Compositions including the same are also provided.Type: ApplicationFiled: March 31, 2010Publication date: April 5, 2012Inventor: Mark D. Mannie
-
Patent number: 8133480Abstract: Disclosed are cysteine variants of interleukin-11 (IL-11) and methods of making and using such proteins in therapeutic applications.Type: GrantFiled: February 24, 2009Date of Patent: March 13, 2012Assignee: Bolder Biotechnology, Inc.Inventor: George N. Cox, III
-
Patent number: 8133700Abstract: The present invention relates to a purified nucleic acid sequence encoding a homologue of human interleukin 10 (IL-10), wherein said IL-10 homologue is expressed during the latent phase of infection by a virus of the herpesvirideae group. The present invention also relates to uses of this polypeptide, in particular for diagnosing disease states and screening for modulator and inhibitor compounds of such polypeptides and in turn the virus itself, screening for infection in vertebrates and biological tissue, cleansing of infected biological tissues, and in the treatment and/or prophylaxis and/or diagnosis of disease caused by a virus of the herpesvirideae group.Type: GrantFiled: November 26, 2004Date of Patent: March 13, 2012Assignee: The University of SydneyInventors: Barry Slobedman, Allison Denise Abendroth, Christina Anne Jenkins
-
Patent number: 8124084Abstract: The present invention relates to a therapeutic polypeptide and methods for its creation and use for modulating an immune response in a host organism in need thereof. In particular, the invention relates to the administration to an organism in need thereof, of an effective amount of a pre-coupled polypeptide complex comprising a lymphokine polypeptide portion, for example IL-15 (SEQ ID NO: 5, 6), IL-2 (SEQ ID NO: 10, 12) or combinations of both, and an interleukin receptor polypeptide portion, for example IL-15Ra (SEQ ID NO: 7, 8), IL-2Ra (SEQ ID NO: 9, 11) or combinations of both, for augmenting the immune system in, for example, cancer, SCID, AIDS, or vaccination; or inhibiting the immune system in, for example, rheumatoid arthritis, or Lupus. The therapeutic complex of the invention surprisingly demonstrates increased half-life, and efficacy in vivo.Type: GrantFiled: May 17, 2006Date of Patent: February 28, 2012Assignee: University of ConnecticutInventors: Leo Lefrancois, Thomas A. Stoklasek
-
Patent number: 8119771Abstract: Products for altering IL-33 activity including antibodies that specifically bind to an epitope with the polypeptide sequence of IL-33 such as antibodies that specifically bind to a protease cleavage region of IL-33 comprising the amino acid sequence of SEQ ID No. 17, or SEQ ID NO. 16, or SEQ ID NO. 10; isolated IL-33 polypeptide(s); and compositions comprising a soluble IL-33 receptor linked to an enzyme capable of cleaving IL-33 or an antibody that binds to IL-33 linked to an enzyme capable of cleaving IL-33. The invention also relates to methods of altering IL-33 activity using the products described herein.Type: GrantFiled: April 28, 2008Date of Patent: February 21, 2012Assignee: The Provost, Fellow and Scholars of the College of the Holy and Undivided Trinity of Queen Elizabeth, Near DublinInventor: Seamus J. Martin
-
Publication number: 20120023614Abstract: The present invention relates to environmental stress-inducible 557 promoter isolated from rice, a recombinant plant expression vector comprising said promoter, a method of producing a target protein by using said recombinant plant expression vector, a method of producing a transgenic plant using said recombinant plant expression vector, a transgenic plant produced by said method, a method of improving resistance of a plant to environmental stress by using said promoter, and a primer set for amplification of said promoter.Type: ApplicationFiled: July 26, 2010Publication date: January 26, 2012Applicant: GENDOCS, INC.Inventors: Haw Jee Chung, Ju Young Park, Mi Na Kim, Yong Woog Lee
-
Publication number: 20120015403Abstract: The expression vectors and methods using an E. coli expression system for the large scale production of IL-29 are described. The vectors utilize the IL-29 coding sequence with specific changes in nucleotides in order to optimize codons and mRNA secondary structure for translation in E. coli. Also included are methods of producing, purifying and pegylating an IL-29 polypeptide.Type: ApplicationFiled: May 24, 2011Publication date: January 19, 2012Inventors: Bruce L. Zamost, Robert M. Dedinsky
-
Publication number: 20120003695Abstract: Lower eukaryotic cells such as Pichia pastoris that normally cannot use galactose as a carbon source but which have been genetically engineered according to the methods herein to use galactose as a sole source of carbon are described. The cells are genetically engineered to express several of the enzymes comprising the Leloir pathway. In particular, the cells are genetically engineered to express a galactokinase, a UDP-galactose-C4-epimerase, and a galactose-1-phosphate uridyltransferase, and optionally a galactose permease. In addition, a method is provided for improving the yield of glycoproteins that have galactose-terminated or -containing N-glycans in cells that have been genetically engineered to produce glycoproteins with N-glycans having galactose residues but which normally lack the enzymes comprising the Leloir pathway comprising transforming the cells with one or more nucleic acid molecules encoding a galactokinase, a UDP-galactose-C4-epimerase, and a galactose-1-phosphate uridyltransferase.Type: ApplicationFiled: February 24, 2010Publication date: January 5, 2012Inventors: Robert C. Davidson, Piotr Bobrowicz, Dongxing Zha
-
Patent number: 8088600Abstract: The present invention relates to at least one novel cynomolgus IL-13 muteins (Mut-IL-13) proteins, antibodies, including isolated nucleic acids that encode at least one Mut-IL-13 protein or antibody, Mut-IL-13 vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.Type: GrantFiled: October 12, 2007Date of Patent: January 3, 2012Assignee: Centocor Ortho Biotech Inc.Inventors: Karyn O'Neil, Leslee Conrad, Dusti Fisher
-
Publication number: 20110318301Abstract: The present invention is directed to a novel naturally occurring human cytokine that is comprised of a heterodimer of interleukin-17 and interleukin-17F designated herein as interleukin 17A/F (IL-17A/F). Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, specific antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases.Type: ApplicationFiled: March 30, 2011Publication date: December 29, 2011Inventors: David P. Arnott, Austin L. Gumey, Philip E. Hass, James M. Lee, Yan Wu
-
Patent number: 8084232Abstract: Isolated polynucleotides encoding Papio cynocephalus Toll-Like Receptor 3 (Baboon TLR3), polypeptides obtainable from expression of these polynucleotides, recombinant cells, and methods of use are disclosed.Type: GrantFiled: September 30, 2009Date of Patent: December 27, 2011Assignee: Centocor Ortho Biotech Inc.Inventors: Jarrat Jordan, Jessica Schreiter, Bethany Swencki-Underwood
-
Patent number: 8080392Abstract: Purified genes encoding a cytokine or composite cytokine from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding these molecules are provided. Methods of using said reagents and diagnostic kits are also provided.Type: GrantFiled: February 10, 2011Date of Patent: December 20, 2011Assignee: Schering CorporationInventors: Jacqueline C. Timans, Stefan Karl-Heinz Pflanz, Robert A. Kastelein, J. Fernando Bazan, Donna Rennick, Rene de Waal Malefyt, Jeanne Cheung
-
Publication number: 20110288269Abstract: The present invention relates to fusion proteins. The invention specifically relates to compositions and methods of Tf-based fusion proteins that demonstrate a high-level expression of transferrin (Tf)-based fusion proteins by inserting a helical linker between two protein domains.Type: ApplicationFiled: April 25, 2011Publication date: November 24, 2011Applicant: UNIVERSITY OF SOUTHERN CALIFORNIAInventors: Wei-Chiang SHEN, Nurmamet AMET, Xiaoying CHEN, Hsin-Fang LEE
-
Patent number: 8062864Abstract: The present invention is directed to antibodies and fragments thereof and humanized versions thereof having binding specificity for IL-6. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-IL-6 antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-IL-6 antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-IL-6 antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with IL-6.Type: GrantFiled: February 5, 2009Date of Patent: November 22, 2011Assignee: Alderbio Holdings LLCInventors: Leon Garcia-Martinez, Anne Elisabeth Carvalho Jensen, Katie Olson, Ben Dutzar, Ethan Ojala, Brian Kovacevich, John Latham, Jeffrey T. L. Smith
-
Patent number: 8034326Abstract: IL-21 variant are provided wherein amino acids have been deleted and/or substituted in the region consisting of amino acid No. 65-96.Type: GrantFiled: April 18, 2006Date of Patent: October 11, 2011Assignee: Novo Nordisk A/SInventors: Siv Annegrethe Hjorth, Kent Bondensgaard, Dennis Madsen
-
Publication number: 20110243888Abstract: The present invention relates to truncated IL-29 mutant molecules and methods of using same. The truncated IL-29 molecules can be used to treat viral infections, such as hepatitis C, autoimmune disorders and various types of cancer.Type: ApplicationFiled: November 20, 2009Publication date: October 6, 2011Inventors: Paul O. Sheppard, Henrik Andersen
-
Publication number: 20110212488Abstract: The present invention relates to specific immortalized avian cell lines expressing telomerase reverse transcriptase (TERT), and exhibiting distinct biologics production patterns. More particularly, the present invention relates to immortalized avian cell line capable of either amplifying Flaviviridae but not capable of amplifying Vaccinia virus strain Copenhagen (W—COP) nor Modified Vaccinia virus Ankara (MVA), or capable of amplifying both Flaviviridae and Poxyiridae. The invention further relates to the use of said immortalized avian cell lines and related methods for producing biologics, including viruses and proteins.Type: ApplicationFiled: May 11, 2010Publication date: September 1, 2011Applicant: TRANSGENE S.A.Inventors: Jean-Marc BALLOUL, Marina KAPFER, Thierry MENGUY
-
Publication number: 20110200562Abstract: The present invention relates to a single-chain or chimeric polypeptide comprising a cytokine and a growth factor linked by at least one amino acid residue, and wherein the chimeric polypeptide enhances the proliferation and/or differentiation of hematopoietic precursor cells. In particular the invention relates to, a chimeric polypeptide comprising the beta-chain of hepatocyte growth factor, and IL-7 linked by at least one amino acid, and wherein the chimeric polypeptide demonstrates pre-pro-B proliferation and growth stimulating activity.Type: ApplicationFiled: August 7, 2009Publication date: August 18, 2011Inventors: Irving Goldschneider, Laijun Lai
-
Patent number: 7982007Abstract: Isolated polynucleotides encoding Cynomolgus monkey Toll-Like Receptor 3 (cynoTLR3), polypeptides obtainable from expression of these polynucleotides, recombinant cells, methods and uses of these are disclosed.Type: GrantFiled: December 23, 2008Date of Patent: July 19, 2011Assignee: Centocor, Inc.Inventors: Heena Beck, Jill Carton
-
Publication number: 20110171687Abstract: The present invention provides unstructured recombinant polymers (URPs) and proteins containing one or more of the URPs. The present invention also provides microproteins, toxins and other related proteinaceous entities, as well as genetic packages displaying these entities. The present invention also provides recombinant polypeptides including vectors encoding the subject proteinaceous entities, as well as host cells comprising the vectors. The subject compositions have a variety of utilities including a range of pharmaceutical applications.Type: ApplicationFiled: November 3, 2010Publication date: July 14, 2011Applicant: Amunix Operating, Inc.Inventors: Volker Schellenberger, Willem P. Stemmer, Chia-wei Wang, Michael D. Scholle, Mikhail Popkov, Nathaniel C. Gordon, Andreas Crameri
-
Publication number: 20110166210Abstract: The present invention provides methods of improving the levels and stability of expression of interleukin-12 family cytokine polypeptides by expressing the alpha and beta subunits of the polypeptides at their determined relative molar ratios that increase the levels and stability of expression of the heterodimer, e.g., in comparison to heterodimer expressed at an equimolar ratio.Type: ApplicationFiled: May 11, 2009Publication date: July 7, 2011Applicant: The Govt. of the U.S.A. as represented by the Sec. of the Dept. of Health and Human ServicesInventors: Barbara K. Felber, George N. Pavlakis
-
Patent number: 7968315Abstract: The expression vectors and methods using an E. coli expression system for the large scale production of IL-29 are described. The vectors utilize the IL-29 coding sequence with specific changes in nucleotides in order to optimize codons and mRNA secondary structure for translation in E. coli. Also included are methods of producing, purifying and pegylating an IL-29 polypeptide.Type: GrantFiled: February 5, 2010Date of Patent: June 28, 2011Assignee: ZymoGenetics, Inc.Inventors: Bruce L. Zamost, Robert M. Dedinsky
-
Publication number: 20110151515Abstract: Methods and compositions are disclosed to engineer plastids comprising heterologous genes encoding immuno-activating domains fused to an extracellular domain (ECD) of a receptor or surface glycoprotein, a growth factor or an enzyme and produced within a subcellular organelle, such as a chloroplast. The immuno-activating domains may include those regions of a protein capable of modulating the interaction between immune effector cells via proteins containing stereoselective binding domains and specific ligands, such as the Fc regions of antibodies. The present disclosure also demonstrates the utility of plants, including green algae, for the production of complex multi-domain fusion proteins as soluble bioactive therapeutic agents.Type: ApplicationFiled: May 11, 2010Publication date: June 23, 2011Applicant: SAPPHIRE ENERGY, INC.Inventors: PETER HEIFETZ, Scott Franklin
-
Publication number: 20110154514Abstract: This invention provides a method for efficiently producing a recombinant protein by allowing the recombinant protein to express in a eukaryotic cell and releasing the expressed recombinant protein to the outside of the cell. The invention provides a polynucleotide used for producing a recombinant protein in a host cell comprising a polynucleotide encoding a glycosylation sequence comprising a transitional endoplasmic reticulum signal sequence and the sequence represented by: Asn-X-(Thr/Ser) (wherein X is an amino acid other than proline) and a polynucleotide encoding a target protein, which would not be efficiently released to the outside of the cell even when a transitional endoplasmic reticulum signal sequence is fused. The polynucleotide releases the target protein to the outside of the host cell via sugar chain modification.Type: ApplicationFiled: June 8, 2009Publication date: June 23, 2011Applicants: Oriental Yeast Co., Ltd.Inventors: Saburo Saito, Nobutake Akiyama, Yuji Ohno
-
Publication number: 20110135596Abstract: A transmembrane fusion protein including ubiquitin or a ubiquitin-like protein, a membrane translocation sequence linked to the C-terminus of the ubiquitin or ubiquitin-like protein, and a biologically active molecule linked to the C-terminus of the membrane translocation sequence is disclosed herein. A polynucleotide encoding the transmembrane fusion protein, a recombinant expression vector including the polynucleotide sequence, a cell transformed by the recombinant expression vector, and a method of delivering the biologically active molecule into a cell using the transmembrane fusion protein are also disclosed.Type: ApplicationFiled: December 3, 2010Publication date: June 9, 2011Applicant: SAMSUNG ELECTRONICS CO., LTD.Inventors: Jae-il LEE, Tae-soo LEE, Young-sun LEE
-
Publication number: 20110129876Abstract: Described herein are molecules, constructs and methods for the production and secretion of polypeptides of interest by host cells, preferably bacterial host cells, and more particularly gram positive bacteria. In particular, the present invention is related to a polynucleic acid encoding a fusion protein and to uses thereof for the secretion of heterologous or homologous polypeptides of interest by a bacterial host cell, preferably Clostridium bacteria. The present invention further relates to methods and constructs for the production and secretion of heterologous or homologous polypeptides of interest proteins by host cells using such polynucleic acids and fusion proteins.Type: ApplicationFiled: July 30, 2009Publication date: June 2, 2011Applicants: Total S.A., Le Centre National De Recherche Scientifique (CNRS), L'Universite de la Mediterranee, L'Universite de Provence, L'Instutut National des Sciences Appliquees (INSA)Inventors: Henri-Pierre Fierobe, Florence Mingardon, Angélique Chanal-Vial
-
Publication number: 20110124048Abstract: Disclosed is a method for coexpressing IL-12 (interleukin-12) and IL-23 (interleukin-23), which comprises the steps of: (a) preparing vectors comprising monocistronic expression constructs of each of nucleotide sequences encoding the p35 subunit, the p40 subunit and the p19 subunit, or preparing a vector comprising a polycistronic expression construct of nucleotide sequences encoding the p35 subunit, the p40 subunit and the p19 subunit; (b) transforming the expression constructs into a host cell; and (c) culturing the transformed host cell to obtain IL-12 and IL-23, a vector for coexpressing IL-12 and IL-23, and a pharmaceutical anti-tumor composition comprising the vectors.Type: ApplicationFiled: January 17, 2008Publication date: May 26, 2011Inventor: Chae-Ok Yun
-
Patent number: 7947474Abstract: Novel polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zyctor17, a novel cytokine receptor. The polypeptides may be used within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides can also be used to block ligand activity in vitro and in vivo. The polynucleotides encoding zyctor17, are located on chromosome 5, and can be used to identify a region of the genome associated with human disease states. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.Type: GrantFiled: October 20, 2006Date of Patent: May 24, 2011Assignee: ZymoGenetics, Inc.Inventors: Cindy A. Sprecher, Scott R. Presnell, Zeren Gao, Theodore E. Whitmore, Joseph L. Kuijper, Mark F. Maurer
-
Patent number: 7947648Abstract: The present invention relates generally to methods and compounds for treating pulmonary disorders, and more specifically to the inhalation administration and use of hIL-4 mutant proteins to treat asthma.Type: GrantFiled: January 11, 2007Date of Patent: May 24, 2011Assignee: Aerovance, Inc.Inventors: Jeffrey Tepper, Adrian Tomkinson
-
Patent number: 7943738Abstract: The present invention provides for IL-17 receptor like polypeptides and nucleic acid molecules encoding the same. The invention also provides vectors, host cells, agonists and antagonists (including selective binding agents), and methods for producing IL-17 receptor like polypeptides. Also provided for are methods for treatment, diagnosis, amelioration, or prevention of diseases with IL-17 receptor like polypeptides.Type: GrantFiled: June 3, 2009Date of Patent: May 17, 2011Assignee: Amgen Inc.Inventors: Eugene Medlock, Richard Yeh, Scott Michael Sibiger, Gary S. Elliott, Hung Q. Nquyen, Shuqian Jing
-
Patent number: 7939297Abstract: Nucleic acids encoding mammalian, e.g., primate, IL-1?, purified IL-1? polypeptides and fragments thereof. Binding proteins, e.g., antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are provided.Type: GrantFiled: April 21, 2010Date of Patent: May 10, 2011Assignee: Schering CorporationInventor: Jacqueline C. Timans
-
Patent number: 7935340Abstract: The present invention is directed to antibodies and fragments thereof having binding specificity for IL-6. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-IL-6 antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-IL-6 antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-IL-6 antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with IL-6.Type: GrantFiled: May 21, 2008Date of Patent: May 3, 2011Assignee: AlderBio Holdings LLCInventors: Leon Garcia-Martinez, Anne Elisabeth Carvalho Jensen, Katie Olson, Ben Dutzar, Ethan Ojala, Brian Kovacevich, John Latham, Jeffrey T. L. Smith
-
Publication number: 20110091936Abstract: The present invention relates generally to glutamine-free cell culture media supplemented with arginine. The invention further concerns the production of recombinant proteins, such as antibodies, in arginine-supplemented glutamine-free mammalian cell culture.Type: ApplicationFiled: August 6, 2010Publication date: April 21, 2011Inventors: Martin GAWLITZEK, Shun Luo, Christina Teresa Petraglia
-
Patent number: 7928198Abstract: Purified genes encoding cytokines from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding this molecule are provided. Methods of using said reagents and diagnostic kits are also provided.Type: GrantFiled: July 17, 2008Date of Patent: April 19, 2011Assignee: Schering CorporationInventors: J. Fernando Bazan, Rene de Waal Malefyt, Yong-Jun Liu, Vassili Soumelis
-
Patent number: 7928197Abstract: The present invention relates to canine and feline proteins. In particular, the present invention discloses feline interleukin-18, feline caspase-1, feline interleukin-12 single chain and canine interleukin-12 single chain proteins. The present invention also includes feline interleukin-18, feline caspase-1, feline interleukin-12 single chain and canine interleukin-12 single chain nucleic acid molecules encoding such proteins, antibodies raised against such proteins and/or inhibitors of such proteins or nucleic acid molecules. The present invention also includes therapeutic compositions comprising such nucleic acid molecules, proteins, antibodies and/or inhibitors, as well as their use to evaluate and regulate an immune response in an animal.Type: GrantFiled: May 28, 2008Date of Patent: April 19, 2011Assignee: Heska CorporationInventor: Ramani S. Wonderling
-
Patent number: 7910331Abstract: CTLA-8 related antigens from mammals, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding said antigens. Methods of using said reagents and diagnostic kits are also provided.Type: GrantFiled: November 11, 2009Date of Patent: March 22, 2011Assignee: Schering CorporationInventors: Daniel M. Gorman, J. Fernando Bazan, Robert A. Kastelein, Gerard Zurawski
-
Patent number: 7906117Abstract: The present invention is directed to therapeutic methods using antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat cachexia, fever, weakness and/or fatigue in a patient in need thereof. In preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level. In another preferred embodiment, the patient's survivability or quality of life will preferably be improved.Type: GrantFiled: November 25, 2008Date of Patent: March 15, 2011Assignee: AlderBio Holdings LLCInventors: Jeffrey T. L. Smith, Randall C. Schatzman, Mark J. Litton, John Latham
-
Publication number: 20110053221Abstract: The present invention relates to novel expression cassettes and vectors for efficiently producing authentic recombinant human proteins from stable cultures of novel human cell lines, the authentic recombinant proteins produced therefrom, and antibodies raised against those authentic recombinant proteins.Type: ApplicationFiled: March 12, 2009Publication date: March 3, 2011Inventors: Ridong Chen, Soon Seog Jeong, Hui Feng
-
Patent number: 7888071Abstract: The invention provides cytokine fusion proteins with an increased therapeutic index, and methods to increase the therapeutic index of such fusion proteins. The fusion proteins of the invention are able to bind to more than one type of cytokine receptor expressed on cells and also bind to more than one cell type. In addition, the fusion proteins of the invention exhibit a longer circulating half-life in a patient's body than the corresponding naturally occurring cytokine.Type: GrantFiled: December 1, 2008Date of Patent: February 15, 2011Assignee: Merck Patent GmbHInventors: Stephen D. Gillies, Pascal Andre Stein, Kin-Ming Lo
-
Patent number: 7875709Abstract: The invention provides mutants of IL-18 with lower affinity to IL-18BP than the wild type IL-18 molecule.Type: GrantFiled: March 16, 2009Date of Patent: January 25, 2011Assignee: Ares Trading S.A.Inventors: Charles A Dinarello, Soo-Hyun Kim
-
Patent number: 7846652Abstract: Interleukin-22 interacts with its receptor, referred to as IL-22R, and instigates a series of reactions, leading to activation of various molecules, such as JAK-1, Tyk2, and others. One can identify molecules which mediate this interaction by measuring the activity of one or more of the molecules in the pathway, to identify agonists and antagonists. These, in turn, are useful therapeutic agents, where inappropriate expression of one of the activated molecules is at issue, and requires amelioration.Type: GrantFiled: July 24, 2006Date of Patent: December 7, 2010Assignee: WyethInventors: Jean-Christophe Renauld, Diane Lejeune, Laure Dumoutier
-
Publication number: 20100291043Abstract: Compositions and methods for delivering immune modulatory molecules to result in a therapeutic effect are disclosed. The compositions and methods use stably integrating lentiviral delivery systems. The methods are useful for therapeutically and prophylactically treating cancer such as leukemia.Type: ApplicationFiled: May 5, 2008Publication date: November 18, 2010Applicant: UNIVERSITY HEALTH NETWORKInventors: Jeffrey A. Medin, Christopher J. Paige
-
Patent number: 7833754Abstract: The present invention provides for nucleic acids improved for the expression of interleukin-12 (IL-12) in mammalian cells. The invention further provides for methods of expressing IL-12 in mammalian cells by transfecting the cell with a nucleic acid sequence encoding an improved IL-12 sequence.Type: GrantFiled: January 12, 2007Date of Patent: November 16, 2010Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Barbara Felber, George N. Pavlakis, Margherita Rosati
-
Patent number: 7834152Abstract: Disclosed herein are mutant IL-15 polypeptides and methods for using these polypeptides to modulate the immune response in a patient.Type: GrantFiled: March 20, 2007Date of Patent: November 16, 2010Assignee: Beth Israel Deaconess Medical Center, Inc.Inventors: Terry B. Strom, Wlodzimierz Maslinski
-
Publication number: 20100278774Abstract: The instant invention provides soluble fusion protein complexes and IL-15 variants that have therapeutic and diagnostic use, and methods for making the such proteins. The instant invention additionally provides methods of stimulating or suppressing immune responses in a mammal using the fusion protein complexes and IL-15 variants of the invention.Type: ApplicationFiled: February 5, 2010Publication date: November 4, 2010Applicant: ALTOR BIOSCIENCE CORPORATIONInventors: Hing C. Wong, Peter Rhode, Xiaoyun Zhu, Kai-ping Han
-
Publication number: 20100278775Abstract: The production of interleukin-24 (IL-24) cytokine in plants is described. A plant optimized nucleic acid molecule encoding a IL-24 polypeptide is disclosed. Also described are genetic constructs comprising a regulatory region operably linked to a plant optimized nucleic acid molecule encoding a IL-24 polypeptide. The regulatory region may be an inducible promoter. Also disclosed are methods of transforming a plant, portion thereof, or plant cell with the genetic construct and method of using a plant, a portion of a plant or a plant cell that express IL-24.Type: ApplicationFiled: August 8, 2008Publication date: November 4, 2010Applicant: Her Majesty the Queen in Right of Canada, as Re- presented by the Minister of Agriculture and Agri-Inventors: Rima Menassa, Alexandra Reid
-
Patent number: 7820181Abstract: Recombinant human parainfluenza virus type 2 (HPIV2) viruses and related immunogenic compositions and methods are provided. The recombinant HPIV2 viruses, including HPIV2 chimeric and chimeric vector viruses, provided according to the invention are infectious and attenuated in permissive mammalian subjects, including humans, and are useful in immunogenic compositions for eliciting an immune responses against one or more PIVs, against one or more non-PIV pathogens, or against a PIV and a non-PIV pathogen. Also provided are isolated polynucleotide molecules and vectors incorporating a recombinant HPIV2 genome or antigenome.Type: GrantFiled: September 18, 2003Date of Patent: October 26, 2010Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Mario H. Skiadopoulos, Brian R. Murphy, Peter L. Collins
-
Publication number: 20100254943Abstract: The invention provides compositions and methods of identifying, modifying and producing modified target molecules, including therapeutic molecules by modification with non-natural amino acids. Certain aspects of the invention include methods of adding a chemical moiety to a target molecule, and the compositions resulting therefrom. Certain aspects of the invention also relate to kits for identifying, modifying and producing modified target molecules described herein.Type: ApplicationFiled: November 2, 2009Publication date: October 7, 2010Applicant: ALLOZYNE, INC.Inventors: Kenneth H. Grabstein, Aijun Wang, Natalie Winblade Nairn, Thomas James Graddis, Stephen McCraith, Deepshikha Datta